Immuneering (NASDAQ: IMRX) CPO awarded 140,000 options at $4.91

Rhea-AI Filing Summary

Immuneering Corp’s chief people officer receives new stock options grant. Leah R. Neufeld was awarded stock options covering 140,000 shares of Class A common stock on February 3, 2026, with an exercise price of $4.91 per share and no purchase price for the options themselves.

The options vest in equal monthly installments over four years starting February 1, 2026, and are scheduled to be fully vested and exercisable on January 1, 2030. Following this grant, Neufeld beneficially owns 140,000 derivative securities directly through this option award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Neufeld Leah R

Role CHIEF PEOPLE OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	140,000	$0.00	--

Holdings After Transaction: Stock Option — 140,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Neufeld Leah R

(Last) (First) (Middle)

245 MAIN STREET

SECOND FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [ IMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF PEOPLE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$4.91	02/03/2026		A		140,000		(1)	02/03/2036	Class A Common Stock	140,000	$0	140,000	D

Explanation of Responses:

1. The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030.

Remarks:

	/s/ Michael D. Bookman, Attorney-in-Fact for Leah R. Neufeld	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Immuneering Corp (IMRX) disclose in this Form 4 filing?

Immuneering Corp reported that Chief People Officer Leah R. Neufeld received stock options for 140,000 shares of Class A common stock. The options were granted on February 3, 2026, and represent a form of equity-based compensation for the executive.

How many Immuneering (IMRX) stock options were granted to Leah R. Neufeld?

Leah R. Neufeld was granted stock options covering 140,000 shares of Immuneering’s Class A common stock. This entire amount is reflected as beneficially owned derivative securities following the reported transaction in the Form 4 filing for February 3, 2026.

What is the exercise price of the new Immuneering (IMRX) stock options?

The stock options granted to Leah R. Neufeld have an exercise price of $4.91 per share. This means she can purchase Immuneering Class A common stock at $4.91 once the options are vested and exercisable, subject to the vesting schedule disclosed.

When do Leah R. Neufeld’s Immuneering (IMRX) options vest and become exercisable?

The options vest in equal monthly installments over four years starting February 1, 2026. According to the filing, they will be fully vested and exercisable on January 1, 2030, providing a long-term incentive structure tied to continued service.

Are the Immuneering (IMRX) options held by Leah R. Neufeld direct or indirect ownership?

The Form 4 indicates that Leah R. Neufeld holds the 140,000 stock options as direct ownership. No indirect ownership entity or special beneficial ownership disclaimer is noted, so the options are attributed directly to her in the filing.

What type of security did Immuneering (IMRX) grant to its chief people officer?

Immuneering granted a derivative security classified as a stock option linked to its Class A common stock. Each option corresponds to one share, with 140,000 underlying shares in total, exercisable at $4.91 per share once vested under the specified schedule.